Skip to main content

Table 1 Pathological and clinical characteristics of the inflammatory breast cancer (IBC) cohort

From: Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer

 

IBC

Total, n (%)

156 (100)

Age (years)

 Median

53

 Range

23–84

  ≤50, n (%)

63 (40.5)

  >50, n (%)

93 (59.5)

Sex, n (%)

 Female

156 (100)

 Male

0 (0)

Stage, n (%)

 III

120 (76.9)

 IV

36 (23.1)

ER status, n (%)

 Negative

89 (57.1)

 Positive

67 (42.9)

PR status, n (%)

 Negative

111 (71.2)

 positive

45 (28.8)

Her2 status, n (%)

 Negative

113 (72.4)

 Positive

43 (27.6)

Subgroups, n (%)

 TNBC

51 (32.7)

 HR/Her2+

33 (21.2)

 HR+/Her2

62 (39.7)

 HR+/Her2+

10 (6.4)

Distant metastases, n (%)

 Yes

98 (62.8)

 No

58 (37.2)

SBR histological grade, n (%)

 I

2 (1.3)

 II

63 (40.4)

 III

91 (58.3)

  1. ER estrogen receptor, Her2 human epidermal growth factor receptor 2, HR hormone receptor, PR progesterone receptor, SBR Scarf Bloom Richardson classification, TNBC triple-negative breast cancer